A peptide longevity platform raised $6.5 million — financing is not clinical evidence

Edited by Samael A. Tejada, Founder & Editor-in-Chief

Money is moving into longevity peptides. Readers should keep two ledgers separate: the capital ledger, which this release fills in, and the evidence ledger, which it does not touch.

What exactly was announced?

A closed, non-brokered private placement: 6,190,475 units at US$1.05 each — each unit pairing a common share with half a share-purchase warrant — for gross proceeds of US$6,499,998.75. The round was led by an investor group organized by Harvey Spevak, Chairman of Equinox Group. The securities carry a statutory hold period of four months plus a day. The company, formerly Sweet Earth Holdings, took its public vehicle through a reverse takeover and expects to trade on the Canadian Securities Exchange under the ticker VLAB.

What does the company do?

Vesalius describes itself as a longevity science and regenerative health platform focused on peptides, biologics, preventative healthcare and performance optimization, built on a prescriber-led model that connects licensed healthcare providers with peptide therapeutics. Proceeds are earmarked to expand the sales team and enter new markets. A prescriber-led structure is a meaningful safeguard compared with the unauthorized direct-to-consumer peptide sellers regulators have been seizing product from — licensed providers and pharmacies are the legitimate channel. It is not, by itself, evidence that any given peptide works.

How should readers weigh financing news?

As a signal about the market, not about the molecules. At $6.5 million, the round is also modest against the broader longevity-investment wave — other ventures have raised hundreds of millions to push a single medicine toward human trials. What would change the evidence ledger for a platform like this is published clinical data on its therapies: controlled trials, named endpoints, peer review. Until those exist, the honest summary of any financing release is the one this company would presumably accept: capital raised, platform expanding, clinical questions unchanged.

Where the evidence stands

• Established: The financing facts (company release via Newswire, November 9, 2026): US$6,499,998.75 gross proceeds, 6,190,475 units at US$1.05, led by a group organized by Harvey Spevak; reverse takeover of Sweet Earth Holdings completed; CSE ticker VLAB expected.
• Preliminary: The platform's therapeutic promise: prescriber-led peptide delivery is a legitimate channel structure, but the clinical evidence for most marketed longevity peptides remains limited and largely preclinical, as this site's peptide coverage grades compound by compound.
• Absent: Clinical evidence in the announcement — the release reports no trial, outcome or safety data for any peptide or service the platform offers.